*For medical professionals reading reference only
1 minute a day, giving you professional "talk" in the tumor circle! (If you need the original text of the document, you can add the editor’s WeChat yxj_oncology to obtain)
1
J Clin Oncol: Treprizumab combined with chemotherapy can significantly improve PFS and OS
▎ Clinical problems:
chemotherapy combined with chemotherapy as the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). It is not yet clear.
A study from J Clin Oncol showed that teriplizumab combined with chemotherapy can significantly improve progression-free survival (PFS) and overall survival (OS) in patients with initial treatment of advanced NSCLC.
▎ Study Protocol: Patients with initially treated advanced NSCLC without EGFR/ALK mutations (N=465) were randomly grouped 2:1, received 240 mg of teriplizumab (n=309) or placebo (n=156) every 3 weeks, and combined with chemotherapy for 4 to 6 cycles, followed by maintenance treatment of teriplizumab or placebo once every 3 weeks. Stratified factors include programmed death ligand-1 expression status, histology, and smoking status. The main endpoint was the PFS determined by the researcher based on RECIST v1.1. Secondary endpoints include OS and security.
▎ Mainly found:
1) During the final PFS analysis, the PFS of the teriplizumab treatment group was significantly prolonged compared with the placebo group (median PFS 8.4 vs 5.6 months, HR=0.49, 95%CI 0.39-0.61; bilateral P<0.0001).>
2) During the interim OS analysis, the OS in the terreprizumab-treated group was significantly prolonged compared with the placebo group (median OS did not reach vs 17.1 months, HR=0.69, 95% CI 0.53-0.92; bilateral P=0.0099).
3) The incidence of in the two groups ≥3 grade adverse events was similar. The treatment effect was similar regardless of the status of programmed death ligand-1.
4) Genomic analysis of whole-exome sequencing of 394 tumor samples showed that in the terreprizumab-treated group, PFS was significantly prolonged in patients with high tumor mutation burden (median PFS was 13.1 vs 5.5 months, P=0.026).
5) Patients with PI3K-Akt signaling pathway mutations achieved significantly better PFS and OS in the teriplizumab-treated group (P ≤ 0.001).
▎ Outlook:
teriplizumab combined with chemotherapy can significantly improve the PFS and OS in patients with initial treatment of advanced NSCLC, and its drug safety is controllable.
References:
[1]https://ascopubs.org/doi/full/10.1200/JCO.22.00727
The top journal essence assistant of clinical literature is online 👇
1. Scan the QR code below
0 jump to " top journal essence " H5 page
2. Click " Download now"
3. Open Doctor Station Appp Click column
4. Find in clinical medicines, " Top magazine essence "
Follow column
Subscribe to the column, read new top magazines every day!
Download Doctor Station Appp, subscribe anytime and anywhere~
This article was first published: Medical World Tumor Channel
Author: Dingchao Jingyao Group
Editor: Sweet
Copyright Statement
This article is original If you need to reprint, please contact the authorization
- End -
*The medical community strives to ensure the accuracy and reliability of the published content when it is approved, but does not make any commitments and guarantees for the timeliness of the published content, as well as the accuracy and completeness of the cited materials (if any), and does not assume any responsibility arising from the outdated, the possible inaccuracy or incompleteness of the cited materials. Please check separately when using this or using it as the basis for decision-making.
